Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives $9.00 Consensus Target Price from Brokerages

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has been given a consensus recommendation of “Buy” by the seven research firms that are presently covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $9.00.

Separately, D. Boral Capital restated a “buy” rating and issued a $3.00 price objective on shares of Reviva Pharmaceuticals in a report on Friday, June 27th.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Several large investors have recently made changes to their positions in RVPH. Raymond James Financial Inc. purchased a new position in shares of Reviva Pharmaceuticals during the fourth quarter valued at approximately $25,000. Geode Capital Management LLC lifted its holdings in shares of Reviva Pharmaceuticals by 11.9% during the fourth quarter. Geode Capital Management LLC now owns 311,701 shares of the company’s stock valued at $564,000 after purchasing an additional 33,205 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Reviva Pharmaceuticals during the fourth quarter valued at approximately $45,000. Tower Research Capital LLC TRC raised its holdings in Reviva Pharmaceuticals by 848.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 26,775 shares of the company’s stock worth $48,000 after acquiring an additional 23,953 shares during the last quarter. Finally, Ameriprise Financial Inc. purchased a new position in Reviva Pharmaceuticals in the 4th quarter worth approximately $84,000. 63.18% of the stock is currently owned by hedge funds and other institutional investors.

Reviva Pharmaceuticals Price Performance

Shares of RVPH opened at $0.46 on Wednesday. Reviva Pharmaceuticals has a one year low of $0.30 and a one year high of $4.28. The company has a 50-day simple moving average of $0.58 and a two-hundred day simple moving average of $0.97. The firm has a market capitalization of $21.91 million, a PE ratio of -0.58 and a beta of -0.05.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.08. Analysts expect that Reviva Pharmaceuticals will post -0.97 EPS for the current fiscal year.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.